See more : Bangkok Bank Public Company Limited (BGKKF) Income Statement Analysis – Financial Results
Complete financial analysis of Ind-Swift Laboratories Limited (INDSWFTLAB.NS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ind-Swift Laboratories Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Norfolk Southern Corporation (0K8M.L) Income Statement Analysis – Financial Results
- SK Telecom Co.,Ltd (SKMD.IL) Income Statement Analysis – Financial Results
- RateGain Travel Technologies Limited (RATEGAIN.BO) Income Statement Analysis – Financial Results
- Bright Lights Acquisition Corp. (BLTS) Income Statement Analysis – Financial Results
- Support.com, Inc. (SPRT) Income Statement Analysis – Financial Results
Ind-Swift Laboratories Limited (INDSWFTLAB.NS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.indswiftlabs.com
About Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) in India. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, antimigraine, Parkinson disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, anticholinergic, sedative, hypnotic, alcohol abstinence, and antineoplastic, as well as various products for ADHD symptoms. It provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, aripiprazole, atorvastatin calcium, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, Clarithromycin, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nitazoxanide, quetiapine, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide. The company also offers early and late phase drug development, process research and development, contract and API manufacturing, and custom chemicals and synthesis; and analytical development, regulatory support, chemistry, impurity profiling, isolation, discovery, identification and characterization, and project management services. It also exports its products. Ind-Swift Laboratories Limited was founded in 1995 and is based in Manimajra, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.81B | 12.07B | 10.39B | 8.91B | 7.80B | 7.57B | 7.65B | 6.97B | 6.53B | 6.60B | 9.65B | 11.36B | 14.09B | 10.49B | 7.85B | 5.90B | 4.58B | 3.50B |
| Cost of Revenue | 8.68B | 6.56B | 6.11B | 5.30B | 4.73B | 4.68B | 4.74B | 4.49B | 4.03B | 4.62B | 8.08B | 9.59B | 11.21B | 8.16B | 6.08B | 4.25B | 3.33B | 2.55B |
| Gross Profit | 4.13B | 5.52B | 4.28B | 3.61B | 3.06B | 2.89B | 2.92B | 2.48B | 2.50B | 1.98B | 1.57B | 1.77B | 2.88B | 2.32B | 1.77B | 1.65B | 1.25B | 953.41M |
| Gross Profit Ratio | 32.27% | 45.70% | 41.20% | 40.51% | 39.29% | 38.18% | 38.10% | 35.60% | 38.33% | 30.00% | 16.23% | 15.62% | 20.45% | 22.16% | 22.57% | 27.91% | 27.32% | 27.22% |
| Research & Development | 0.00 | 425.74M | 327.16M | 66.90M | 3.93M | 5.33M | 3.10M | 1.92M | 4.22M | 82.16M | 77.94M | 76.04M | 0.00 | 56.84M | 52.27M | 49.38M | 36.84M | 54.45M |
| General & Administrative | 367.83M | 205.16M | 196.21M | 172.90M | 173.80M | 171.29M | 176.47M | 61.59M | 159.63M | 95.67M | 211.34M | 222.21M | 815.30M | 233.53M | 181.00M | 159.49M | 141.29M | 131.08M |
| Selling & Marketing | 427.96M | 430.61M | 437.42M | 320.84M | 248.10M | 251.72M | 314.97M | 217.16M | 322.06M | 312.32M | 170.98M | 294.77M | 0.00 | 182.15M | 167.55M | 118.59M | 70.72M | 73.95M |
| SG&A | 795.79M | 635.77M | 633.62M | 493.74M | 421.91M | 423.01M | 491.45M | 278.75M | 481.68M | 407.99M | 382.33M | 516.98M | 815.30M | 415.68M | 348.55M | 278.08M | 212.01M | 205.03M |
| Other Expenses | 1.33B | 335.00M | 139.96M | 34.80M | -5.96M | 29.12M | 39.86M | 30.19M | 26.10M | 13.18M | 19.74M | 108.60M | 845.18M | 394.37M | 376.31M | 322.45M | 268.84M | 182.91M |
| Operating Expenses | 2.12B | 3.80B | 3.36B | 2.50B | 2.33B | 2.35B | 2.30B | 2.14B | 2.17B | 1.76B | 1.55B | 1.57B | 1.17B | 866.89M | 777.13M | 649.91M | 517.69M | 442.39M |
| Cost & Expenses | 10.82B | 10.35B | 9.46B | 7.80B | 7.07B | 7.03B | 7.04B | 6.63B | 6.20B | 6.39B | 9.63B | 11.15B | 12.38B | 9.03B | 6.86B | 4.90B | 3.84B | 2.99B |
| Interest Income | 183.71M | 58.72M | 5.62M | 5.29M | 13.64M | 25.78M | 38.46M | 9.22M | 7.11M | 35.56M | 34.46M | 36.14M | 121.82M | 10.65M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 511.04M | 921.66M | 914.53M | 933.53M | 1.02B | 839.60M | 269.32M | 746.97M | 907.52M | 993.05M | 873.21M | 727.37M | 847.26M | 569.62M | 510.62M | 469.55M | 292.72M | 258.76M |
| Depreciation & Amortization | 533.03M | 570.80M | 1.31B | 872.92M | 898.28M | 1.04B | 866.16M | 882.56M | 847.24M | 842.90M | 657.40M | 543.35M | 398.61M | 385.16M | 419.00M | 294.09M | 199.10M | 123.06M |
| EBITDA | 6.86B | 2.36B | 2.39B | 2.06B | 1.78B | 2.46B | 1.51B | 1.23B | 1.08B | 582.26M | 110.24M | 82.46M | 1.76B | 1.86B | 1.43B | 1.26B | 884.51M | 627.27M |
| EBITDA Ratio | 53.57% | 21.76% | 23.94% | 22.29% | 22.15% | 21.70% | 19.78% | 16.20% | 16.20% | 14.10% | 10.43% | 7.85% | 14.98% | 17.56% | 18.90% | 21.83% | 20.36% | 17.91% |
| Operating Income | 2.01B | 1.82B | 924.23M | 1.11B | 739.60M | 444.90M | 474.20M | -583.59M | -853.92M | -1.45B | -1.44B | -1.30B | 1.71B | 1.46B | 995.26M | 997.27M | 732.83M | 511.02M |
| Operating Income Ratio | 15.68% | 15.04% | 8.90% | 12.45% | 9.49% | 5.88% | 6.19% | -8.37% | -13.07% | -21.91% | -14.92% | -11.42% | 12.17% | 13.89% | 12.67% | 16.90% | 16.01% | 14.59% |
| Total Other Income/Expenses | 3.81B | -950.00M | -798.91M | -929.51M | -928.97M | 51.49M | -258.83M | -898.00M | -1.16B | -1.65B | -1.44B | -1.40B | -849.35M | -558.97M | -491.05M | -497.66M | -340.14M | -265.57M |
| Income Before Tax | 5.82B | 865.21M | 125.32M | 180.09M | -197.71M | 591.71M | 359.30M | -553.40M | -827.80M | -1.43B | -1.42B | -1.19B | 865.47M | 862.48M | 504.21M | 499.61M | 392.69M | 245.45M |
| Income Before Tax Ratio | 45.42% | 7.17% | 1.21% | 2.02% | -2.54% | 7.82% | 4.69% | -7.94% | -12.67% | -21.71% | -14.72% | -10.46% | 6.14% | 8.23% | 6.42% | 8.47% | 8.58% | 7.01% |
| Income Tax Expense | 1.60B | 386.85M | 146.81M | 211.56M | 14.17M | 207.31M | 140.11M | -161.79M | -240.94M | -240.01M | -200.51M | -8.77M | -917.75M | -32.14M | -59.65M | 95.69M | 78.48M | 63.06M |
| Net Income | 4.21B | 475.97M | -21.49M | -31.47M | -211.88M | 384.40M | 219.20M | -391.61M | -586.88M | -1.19B | -1.22B | -1.18B | 891.61M | 894.62M | 563.86M | 403.92M | 314.21M | 182.39M |
| Net Income Ratio | 32.86% | 3.94% | -0.21% | -0.35% | -2.72% | 5.08% | 2.86% | -5.62% | -8.98% | -18.07% | -12.64% | -10.38% | 6.33% | 8.53% | 7.18% | 6.84% | 6.86% | 5.21% |
| EPS | 71.24 | 8.06 | -0.36 | -0.53 | -4.28 | 7.04 | 4.86 | -9.21 | -14.33 | -29.14 | -29.79 | -30.09 | 24.86 | 29.76 | 20.86 | 16.22 | 13.63 | 8.21 |
| EPS Diluted | 71.24 | 8.06 | -0.36 | -0.53 | -4.28 | 7.04 | 4.86 | -9.20 | -14.33 | -29.14 | -29.79 | -29.84 | 23.98 | 27.57 | 20.19 | 15.31 | 13.43 | 8.12 |
| Weighted Avg Shares Out | 59.09M | 59.09M | 59.09M | 59.09M | 49.46M | 54.64M | 45.07M | 42.54M | 40.95M | 40.96M | 40.96M | 39.20M | 35.87M | 29.44M | 27.03M | 24.90M | 23.05M | 22.20M |
| Weighted Avg Shares Out (Dil) | 59.09M | 59.09M | 59.09M | 59.09M | 49.46M | 54.64M | 45.07M | 42.55M | 40.96M | 40.96M | 40.96M | 39.53M | 37.19M | 31.78M | 27.92M | 26.38M | 23.39M | 22.45M |
Source: https://incomestatements.info
Category: Stock Reports